Product Program year 2020 Source: CMS Open Payments

Savaysa

Drug Thrombosis

NDC 65597-201-30

Open in the dashboard

General payments

$532,987

20 payments

Research payments

$199,260

75 payments

Through program year 2020, $532,987 in general payments and $199,260 in research payments were reported against Savaysa (Thrombosis).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $246,451 5
2020 Research $197,076 74
2019 General $286,536 15
2019 Research $2,184 1

Breakdown

Who paid General payments · program years 2019–2020
  1. Daiichi Sankyo Inc. $532,987 20 payments
Top recipients General payments · program year 2020
  1. Brigham And Womens Hospital Teaching hospital · MA $244,306 99% · 2 payments
  2. Fariba Goodarzian Pediatric Radiology · Los Angeles, CA $1,230 <1% · 1 payment
  3. Adrian Dibisceglie Gastroenterology · Saint Louis, MO $540 <1% · 1 payment
  4. Neil Goldenberg Pediatric Hematology-Oncology · St Petersburg, FL $375 <1% · 1 payment

Each share is of general payments naming this product in 2020.

Specialties paid General payments · program year 2020
  1. Pediatric Radiology Radiology $1,230 57% · 1 practitioner
  2. Gastroenterology Internal Medicine $540 25% · 1 practitioner
  3. Pediatric Hematology-Oncology Pediatrics $375 17% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. Massachusetts $244,306 99% · 1 recipient
  2. California $1,230 <1% · 1 recipient
  3. Missouri $540 <1% · 1 recipient
  4. Florida $375 <1% · 1 recipient

Each share is of general payments naming this product in 2020 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

2,286

Prescriptions dispensed, refills included

Drug cost

$964,277

Paid at the pharmacy, in all

Prescribers

168

With 11 or more claims of it

Medicare Part D drugs matched to Savaysa, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Savaysa Edoxaban Tosylate Same name 168 2,286 $964,277

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Deirdre Heersink Geriatric Medicine ME 36 $7,476 None on record
Pooja Patel Physician Assistant SC 35 $15,893 None on record
Joel Reginelli Cardiology OH 30 $4,713 None on record
Samuel Goldhaber Cardiology MA 28 $20,447 None on record
Georgina Aguirre Nurse Practitioner ME 27 $5,618 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
20 general · 75 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record